Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study
Diana Cortés‐Selva(Johnson & Johnson (United States)), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center), Karl C. Nielsen(Janssen (United States)), Danielle Trancucci(Centre Hospitalier Universitaire de Nantes), Cuc Davis(Janssen (United States)), Niels W.C.J. van de Donk(Oncode Institute), On Say Lau(Janssen (United States)), Shun Xin Wang Lin(Centre Hospitalier Universitaire de Nantes), Deeksha Vishwamitra(Janssen (United States)), Rachel Kobos(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Nizar J. Bahlis(Institute of Cancer Research), Suzette Girgis(Centre Hospitalier Universitaire de Nantes), Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Clarissa Uhlar(University of Pennsylvania), Jaymala Patel(Janssen (United States)), Lixia Pei(Janssen (United States)), Liviawati S. Wu(Janssen (United States)), Sarah Stein(Harvard Pilgrim Health Care), Philippe Moreau(Centre National de la Recherche Scientifique), Rengasamy Boominathan(Janssen (United States)), Sheri Skerget(Translational Genomics Research Institute), Jenna D. Goldberg(Centre Hospitalier Universitaire de Nantes), Tatiana Perova(Janssen (United States))
Cited by 60
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Serum amyloid A, the major vertebrate acute‐phase reactant
|European Journal of Biochemistry|1999|1.1k